Aya Albittar
YOU?
Author Swipe
View article: Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up Open
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analy…
View article: Development and validation of predictive models of early immune effector cell–associated hematotoxicity
Development and validation of predictive models of early immune effector cell–associated hematotoxicity Open
Immune effector cell–associated hematotoxicity (ICAHT) is associated with morbidity and mortality after chimeric antigen receptor (CAR) T-cell therapy. To date, the factors associated with ICAHT are poorly characterized, and there is no va…
View article: Correction: Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
Correction: Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity Open
View article: A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma Open
Introduction Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment of patients with malignant melanoma. However, improving therapeutic efficacy requires identifying drug combinations that elicit durable responses wi…
View article: Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients
Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients Open
Human herpesvirus 6B (HHV-6B) reactivation and disease are increasingly reported after chimeric antigen receptor (CAR) T-cell therapy (CARTx). HHV-6 reactivation in the CAR T-cell product was recently reported, raising questions about prod…
View article: Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity Open
View article: Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: feasibility, safety and efficacy in a real-world setting
Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: feasibility, safety and efficacy in a real-world setting Open
View article: Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsedrefractory chronic lymphocytic leukemia 6-year follow-up
Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsedrefractory chronic lymphocytic leukemia 6-year follow-up Open
BACKGROUNDWe observed high efficacy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) treated on a phase I/II clinical trial with a defined-composition (1:1 ratio of CD8+:CD4+) CD19 CAR T-cell product (NCT018656…
View article: Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL Open
High response rates have been reported after CD19-targeted chimeric antigen receptor–modified (CD19 CAR) T-cell therapy for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), yet the factors associated with duration of response …
View article: P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL
P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL Open
Topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical Background: CD19-targeted chimeric antigen receptor-modified (CD19 CAR) T-cell therapy is transforming the treatment of patients with relapsed/refractory (R/R) B cell …
View article: Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience Open
Introduction Immune checkpoint inhibitor (ICI) pneumonitis causes substantial morbidity and mortality. Estimates of real-world incidence and reported risk factors vary substantially. Methods We conducted a retrospective review of 419 patie…
View article: Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study Open
Background Immune checkpoint inhibitors (ICI), combined with hypomethylating agents, can be used to treat acute myeloid leukemia (AML), but this strategy results in a high rate of pneumonitis. The authors sought to determine risk factors f…
View article: Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases
Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases Open
View article: Incidence of Pneumonitis After Immune Checkpoint Inhibitor Therapy in Patients with Acute Myeloid Leukemia
Incidence of Pneumonitis After Immune Checkpoint Inhibitor Therapy in Patients with Acute Myeloid Leukemia Open